![Reshma Rangwala](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Vermögen: 517 144 $ am 31.05.2026
Reshma Rangwala is currently Chief Medical Officer & Head of Research at Karyopharm Therapeutics, Inc. since 2022.
Former positions include Chief Medical Officer at Aravive, Inc. from 2020 to 2022, Vice President-Medical at Genmab, Inc. from 2017 to 2020, and Executive Clinical Director at Merck & Co., Inc. from 2012 to 2017.
Education includes undergraduate studies at Duke University and a doctorate from The University of Cincinnati College of Medicine.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 14.05.2026 | 56.829 ( 0,25 % ) | 517 144 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| KARYOPHARM THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2022 |
| Unternehmen | Position | Ende |
|---|---|---|
| ARAVIVE, INC. | Technik-/Wissenschafts-/F&E-Leiter | 28.03.2022 |
Genmab, Inc.
 Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Creates and develops human antibodies for the treatment of life-threatening and debilitating diseases | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2020 |
| MERCK & CO., INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2017 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 6 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Genmab, Inc.
Genmab, Inc. Miscellaneous Commercial ServicesCommercial Services Creates and develops human antibodies for the treatment of life-threatening and debilitating diseases | Commercial Services |
The University of Cincinnati College of Medicine
 The University of Cincinnati College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Aravive, Inc.
 Aravive, Inc. BiotechnologyHealth Technology Develops therapies for solid tumors and hematologic malignancies | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
